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Abstract
Aims Insulin-like growth factor binding protein-4 (IGFBP-4) fragments have been shown to predict the risk of major adverse
cardiovascular events, including segment-elevation myocardial infarction, in patients with acute coronary syndrome. We eval-
uated the prognostic value of the carboxy-terminal fragment of IGFBP-4 (CT-IGFBP-4) for all-cause mortality in emergency
room patients with acute heart failure (AHF).
Methods and results CT-IGFBP-4, N-terminal pro brain natriuretic peptide (NT-proBNP), and C-reactive protein (CRP) were
measured at admission from the lithium-heparin plasma of 156 patients with AHF. All-cause mortality was recorded for 1 year.
Receiver operator characteristic (ROC) curves, Kaplan–Meier, and Cox proportional hazard ratio analyses were performed to
evaluate the prognostic value of the various clinical variables, CT-IGFBP-4, NT-proBNP, CRP, and their combinations. During
1 year of follow-up, 52 (33.3%) patients died. CT-IGFBP-4 only weakly correlated with NT-proBNP (Pearson correlation coeffi-
cient r = 0.16, P = 0.044) and did not correlate with CRP (r = 0.08, P = 0.35), emphasizing the different nature of these bio-
markers. The receiver operator characteristic area under the curve (ROC AUC) of CT-IGFBP-4 for the prediction of all-cause
mortality (0.727) was significantly higher than that of NT-proBNP (0.680, P = 0.045) and CRP (0.669, P = 0.016). The combina-
tion of CT-IGFBP-4, NT-proBNP, and CRP predicted mortality significantly better (ROC AUC = 0.788) than any of the biomarkers
alone (P< 0.01 for all). The addition of CT-IGFBP-4 to a clinical prediction model that included age, gender, systolic blood pres-
sure, creatinine, and sodium levels, as well as the history of previous heart failure, coronary artery disease, and hypertension
significantly improved the mortality risk prediction (ROC AUC 0.774 vs. 0.699, P = 0.025). Cox hazard analysis indicated that
elevated CT-IGFBP-4 was independently associated with 1 year mortality (hazard ratio 3.26, P = 0.0008) after adjustment
for age, gender, history of previous heart failure, coronary artery disease, hypertension, chronic kidney failure, history of di-
abetes, heart rate, haemoglobin, plasma sodium, NT-proBNP, CRP, cystatin C, and elevated cardiac troponin I or T. Patients
with increased levels of either two or three of the biomarkers CT-IGFBP-4, NT-proBNP, and CRP had significantly higher mor-
tality risk (adjusted hazard ratio 10.04, P < 0.0001) than patients with increased levels of one or none of the biomarkers.
Conclusions CT-IGFBP-4 was independently associated with all-cause mortality in patients with AHF. Compared with single
biomarkers, the combination of CT-IGFBP-4, NT-proBNP, and CRP improved the prediction of all-cause mortality in patients
with AHF.
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Introduction
Acute heart failure (AHF) is defined as new-onset or worsen-
ing of symptoms and signs of heart failure (HF)1 and often re-
quires rapid hospital admission and intensification of therapy.
In the USA and Europe, AHF is the principal cause of un-
planned hospital admissions in patients aged 65 years or
older and a leading contributor to health care costs.2,3
Several epidemiological studies have shown high in-hospital
mortality rates (from 4% to 28%), as well as poor short-term
and medium-term prognoses for patients with AHF.2,4
Despite major achievements in the treatment of chronic
HF in recent decades, achievements which led to a marked
improvement in long-term survival,5 the outcomes of AHF
remain poor, with 1 year all-cause mortality and rehospitali-
zation rates reaching 17.4% and 43.9%, respectively.6 In
the recent European Society of Cardiology Heart Failure
Long-Term registry, the 1 year mortality rate was 23.6% for
AHF.7
Biomarkers play a key role in the diagnosis of HF. Brain na-
triuretic peptide (BNP) and its amino-terminal precursor frag-
ment (NT-proBNP) are diagnostic HF biomarkers produced by
myocardial cells in response to myocardial wall stress. NT-
proBNP can also be used for HF outcome prediction, along
with other clinical factors, such as blood pressure and kidney
function.8–10 Nevertheless, mortality risk prediction in AHF is
challenging, and accurate prognostication is the key for
selecting the appropriate intensity of therapeutic interven-
tions and follow-up.
The search for prognostic biomarkers of HF, which could
be used alone or in combination with NT-proBNP, is an
urgent task of clinical chemistry. Various circulating
biomarkers, including C-reactive protein (CRP), cardiac tropo-
nins, galectin-3, mid-regional proadrenomedullin, growth
differentiation factor-15, and soluble suppression of
tumorigenicity-2, have been investigated for outcome pre-
diction of HF.11–13
The carboxy-terminal fragment of insulin-like growth factor
binding protein-4 (CT-IGFBP-4) is one of the products of pro-
teolytic cleavage of IGFBP-4 mediated by pregnancy-
associated plasma protein-A (PAPP-A).14 In turn, PAPP-A is
known to be involved in insulin-like growth factor (IGF)-de-
pendent activation of the proliferation of smooth muscle cells
within atherosclerotic plaques and the resultant destabiliza-
tion of the plaques.15,16 Recently, CT-IGFBP-4 was shown to
provide incremental prognostic information on cardiovascular
events and mortality in patients with diagnosed segment
(ST)-elevation myocardial infarction.17 As progressive HF is of-
ten caused by ischaemic heart disease and often follows
acute myocardial infarction (AMI), we hypothesized that
CT-IGFBP-4 could also be utilized as a biomarker for the prog-
nosis of AHF outcomes. Thus, the goal of this study was to as-
sess CT-IGFBP-4 for the prognosis of outcomes of patients
with AHF.
Materials and methods
Design of the immunoassay for CT-IGFBP-4
measurements
The monoclonal antibodies IBP163, IBP182 conjugated
with horseradish peroxidase (IBP182HRP), recombinant
human CT-IGFBP-4, amino-terminal fragment of IGFBP-4
(NT-IGFBP-4), and IGFBP-4 were obtained from HyTest
Ltd, Turku, Finland. In the sandwich immunoassay for
CT-IGFBP-4 measurement, mAb IBP163 (specific to the
proteolytic neoepitope of CT-IGFBP-4) was used as a
capture antibody, and mAb IBP182HRP (recognizing both
full-length IGFBP-4 and CT-IGFBP-4) was used as a detec-
tion antibody.
Briefly, the immunoassay method was performed as fol-
lows: 10 mg/L of the capture monoclonal antibodies
(IBP163) were absorbed on the high-binding polystyrene
96-well plate (Corning, New York, USA) in phosphate buff-
ered saline (PBS; 20 mM potassium phosphate, 150 mM
NaCl, pH 7.4), 100 μL/well (60 min at room temperature
with constant shaking). The plates were washed with PBS
with 0.1% Tween 20 (PBST). The calibrators or analysed
samples were diluted in PBST that contained 225 mmol/L
NaCl (50 μL/well), and mAb IBP182HRP in PBST that
contained 225 mmol/L NaCl (2 mg/L, 50 μL/well) was sub-
sequently added. The plates were then incubated for
30 min at room temperature with constant shaking.
The plates were washed with PBST, and the substrate
solution (0.4 mmol/L 3,3′,5,5′-tetramethylbenzidine in
100 mmol/L Na-acetate buffer, pH 4.5, with 0.01% H2O2;
100 μL/well) was added. The reaction was stopped with
2 mol/L H3PO4, and the absorbance (λ = 450 nm) was
measured.
Validation of CT-IGFBP-4 assay
The analytical detection limit, within-assay imprecision
coefficient of variation (CV), total imprecision CV, and linear
range were defined for the IBP163-IBP182HRP CT-IGFBP-4
assay. In recovery studies, three concentrations of the
calibrator (30, 100, and 300 ng/mL) were spiked into
pooled normal lithium-heparin plasma free of the analyte.
The concentrations of IGFBP-4 and NT-IGFBP-4 in the
cross-reaction studies were 1000 ng/mL. The sandwich
immunoassay IBP163-IBP182HRP had the following charac-
teristics: cross-reactivity to IGFBP-4 and NT-IGFBP-4 < 2%,
linear range 0.3–6 ng/mL, analytical limit of detection
0.15 ng/mL, within-assay imprecision CV < 6.0%, and total
imprecision CV < 9.7%. Recovery of the assay was 82%,
86%, and 87% for 300, 100, and 30 ng/mL CT-IGFBP-4,
respectively.
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Patients and study design
The study was performed in accordance with the current re-
vision of the Helsinki Declaration. The original study popula-
tion consisted of 620 consecutive patients hospitalized with
AHF. Patients were enrolled at 14 hospitals in Finland be-
tween February and May 2004, as previously described.10,18
Mortality data were obtained from the Finnish National
Population Register. Follow-up was completed for all 156 pa-
tients. After collection, the lithium-heparin plasma samples
were aliquoted and stored at 80 °C until analysis. Long-term
stability of IGFBP-4 fragments at 80 °C was previously dem-
onstrated.19 For the purposes of this study, lithium-heparin
plasma samples of 156 patients were randomly selected. At
baseline, demographic and past medical history data were
collected. Cardiac troponin T, NT-proBNP, plasma creatinine
(all from Roche Diagnostics, Basel, Switzerland), cardiac tro-
ponin I (Abbott Diagnostics, Abbott Park, IL, USA), and
cystatin C were analysed in a central laboratory. CRP,
haemoglobin, and sodium levels were analysed locally with
standard methods. Admission samples were used for the
analysis.
Patients were followed for 1 year. One month and 1 year
all-cause mortality were the endpoints of the study. All pa-
tients provided written informed consent.
Statistical analysis
We used the Student’s t-test and Mann–Whitney U test to
assess group-specific differences in the continuous and cat-
egorical variables, respectively. Clinical prognostic variables
(age, gender, systolic blood pressure, creatinine, and so-
dium levels, as well as the history of previous HF, coronary
artery disease, and hypertension) were used to build a
baseline model for mortality risk prediction in the patient
cohort (the ‘clinical prediction model’). We performed re-
ceiver operator characteristic (ROC) curve analysis to inves-
tigate the predictive value of clinical variables, NT-proBNP,
CT-IGFBP-4, CRP, and their combinations in the clinical pre-
diction model. Log-transformation and subsequent logistic
regression were performed to evaluate the analyte combi-
nations in the ROC curve analysis. The cut-off values for
NT-proBNP, CT-IGFBP-4, and CRP were derived from the
ROC curves and were defined as the values that provided
the maximal sum of the sensitivity and specificity.
We used the Cox proportional hazards model to estimate
the hazard ratios (HRs) of all-cause mortality in relation to
NT-proBNP, CT-IGFBP-4, CRP, and other variables. The values
below the cut-off levels were accepted as the reference
groups in these models. To identify independent predictors,
a forward and backward stepwise procedure was used to
choose the final model; variables retained in the model were
considered significant at P < 0.10. The multivariate model
included NT-proBNP, CT-IGFBP-4, CRP, cystatin C, age, gen-
der, previous diagnosis of HF, coronary artery disease, hyper-
tension, chronic kidney failure, history of diabetes, heart rate,
haemoglobin, plasma sodium, and elevated cardiac troponin
T or cardiac troponin I.
Cumulative event rates were estimated using the
Kaplan–Meier method and were compared using the log-rank
test.
Pearson’s correlation coefficient (r) was used to assess the
interrelationships of NT-proBNP, CT-IGFBP-4, and CRP. Values
of P < 0.05 were considered statistically significant, and all
tests were two sided. The software package XLSTAT
(Addinsoft SARL, Paris, France) was used to perform statistical
analyses.
Results
The baseline characteristics of the study population are
shown in Table 1. Fifty-two patients (33.3%) met the end-
point (all-cause mortality) during the 1 year follow-up.
The NT-proBNP, CT-IGFBP-4, and CRP concentration ranges
of the study cohort were 69–52 484 pg/mL, 9.4–1121 ng/mL,
and 0–257 mg/L, respectively. NT-proBNP only weakly corre-
lated with CT-IGFBP-4 (Pearson correlation coefficient
r = 0.16, P = 0.044; Figure 1A), which emphasizes the different
nature of these biomarkers. No correlation was identified be-
tween CT-IGFBP-4 and CRP (r = 0.08, P = 0.35; Figure 1B) or
NT-proBNP and CRP (r = 0.06, P = 0.45; Figure 1C).
Both NT-proBNP and CT-IGFBP-4 were significantly ele-
vated in the non-survivors compared with those in the survi-
vors (Table 1 and Figure 2). NT-proBNP and CT-IGFBP-4 were
also significantly elevated in the patients who died within
1 month (P = 0.022 and P = 0.0003, respectively). CRP was
not significantly elevated in the non-survivors (P = 0.077
and P = 0.076 for mortality at 1 month and 1 year,
respectively).
The abilities of NT-proBNP, CT-IGFBP-4, and CRP, as well as
clinical variables to predict all-cause mortality, both at
1 month and 1 year, were investigated via receiver operator
characteristic area under the curve (AUC) analysis (Figure 3
and Table 2).
CT-IGFBP-4 and NT-proBNP had similar properties for the
prediction of short-term (1 month) mortality; however,
CT-IGFBP-4 was better at the prediction of 1 year mortality.
Both CT-IGFBP-4 and NT-proBNP were significantly better
than CRP. Single NT-proBNP and CT-IGFBP-4 demonstrated
higher ROC AUC values for 1 month than for the 1 year pe-
riod. Combining CT-IGFBP-4 with NT-proBNP improved both
1 month and 1 year mortality prediction compared with
NT-proBNP alone. Similarly, the combination of NT-proBNP
and CRP predicted mortality better than NT-proBNP alone.
However, the addition of CRP to the combination of
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NT-proBNP and CT-IGFBP-4 further increased the prognosis
of both 1 month and 1 year mortality compared with
NT-proBNP or CT-IGFBP-4.
The addition of CT-IGFBP-4 to the clinical prediction model
improved the mortality risk prediction for both the 1 month
and 1 year follow-up periods (Table 2). Although NT-proBNP
and CRP individually did not significantly add to the clinical
prediction model, combining the clinical model with all three
biomarkers (CT-IGFBP-4, NT-proBNP, and CRP) provided the
best prognostic value.
The optimal cut-off values of NT-proBNP, CT-IGFBP-4, and
CRP for predicting all-cause mortality at 1 year in patients
with AHF were 3078 pg/mL, 92.5 ng/mL, and 8.9 mg/L, re-
spectively. These cut-off values corresponded to 85% sensi-
tivity and 47% specificity for NT-proBNP, 81% sensitivity and
58% specificity for CT-IGFBP-4, and 70% sensitivity and 60%
specificity for CRP.
Table 2 presents the HRs for all-cause mortality by applying
the cut-off values previously defined of circulating
NT-proBNP, CT-IGFBP-4, and CRP concentrations and their
combinations. In the unadjusted univariate model, increased
NT-proBNP, CT-IGFBP-4, and CRP were statistically significant
predictors of all-cause mortality. Simultaneous inclusion of
NT-proBNP, CT-IGFBP-4, and CRP in the multivariate model,
along with standard clinical variables, attenuated the HRs to
a certain degree; however, all three biomarkers remained in-
dependent predictors of mortality at both 1 month and
1 year.
The combination of NT-proBNP, CT-IGFBP-4, and CRP strat-
ified patients so that two or three elevated biomarkers
Table 1 Baseline demographic and clinical characteristics as a function of all-cause mortality during 1 year of follow-up
Total (n = 156) Non-survivors (all-cause mortality) (n = 52)Survivors (n = 104)P value
Age; mean (SD) 76.7 (9.9) 79.1 (9.8) 75.5 (9.7) 0.032
Mean; n = (%) 73 (47) 22 (42) 51 (49) 0.43
Underlying diseases; n = (%)
Previous diagnosis of HF 100 (64) 37 (71) 63 (61) 0.20
Coronary artery disease 97 (62) 32 (62) 65 (63) 0.91
AMI, history 45 (29) 16 (31) 29 (28) 0.71
Hypertension 87 (56) 30 (58) 57 (55) 0.73
Stroke, cerebral infarction 24 (15) 11 (21) 13 (13) 0.16
Diabetes (type I or II) 52 (33) 19 (37) 33 (32) 0.55
Chronic obstructive pulmonary disease 24 (15) 9 (17) 15 (14) 0.64
Peripheral arterial disease 13 (8) 4 (8) 9 (9) 0.84
Hypercholesterolemia 31 (20) 8 (15) 23 (22) 0.32
Smoking 21 (13) 7 (13) 14 (13) 1
Ex-smoker 17 (11) 5 (10) 12 (12) 0.72
Medication at admission; n = (%)
ß-blocker 97 (62) 35 (67) 62 (60) 0.35
ACEI/ARB 84 (54) 26 (50) 58 (56) 0.50
Furosemide 86 (55) 32 (62) 54 (52) 0.26
Dihydropyridine Ca blocker 21 (13) 6 (12) 15 (14) 0.62
ASA 63 (40) 21 (40) 42 (40) 1
Warfarin 41 (26) 18 (35) 23 (22) 0.10
Lipid lowering 45 (29) 13 (25) 32 (31) 0.46
Spironolactone 16 (10) 9 (17) 7 (7) 0.041
ICD; n = (%) 8 (5) 1 (2) 7 (7) 0.20
Clinical presentation
Systolic blood pressure,1
mmHg; mean (SD); N = 152
149 (36) 139 (34) 154 (36) 0.014
Diastolic blood pressure,1
mmHg; mean (SD); N = 152
83 (20) 77 (19) 86 (20) 0.009
LVEF1 (%); mean (SD); N = 79 42 (16) 43 (19) 42 (14) 0.78
Heart rate,1 beats/min; mean (SD); N = 151 93 (29) 97 (36) 90 (25) 0.21
Na,1 mmol/L; median (IQR); N = 149 139 (135–141) 138 (134–141) 139 (136–141) 0.061
Haemoglobin,1 g/L, median (IQR); N = 147 128 (115–139) 125 (115–135) 130 (114–142) 0.157
Cystatin C, mg/L, median (IQR) 1.33 (111–1.64) 1.47 (1.33–1.79) 1.21 (0.96–1.46) 0.0001
Creatinine, μmol/L, median (IQR) 87.0 (73.0–118.0) 106.0 (81.5–125.8) 84.5 (71.8–109.3)0.032
CRP,1 mg/L; median (IQR); N = 150 9.0 (3.6–20.4) 15.0 (6.9–27.5) 7.0 (3.0–15.6) 0.076
Elevated cTn1,2; n = (%); N = 126 52/126 (41) 20/42 (48) 32/84 (38) 0.36
CT-IGFBP-4, ng/mL; median (IQR) 106 (67–160) 136 (104–203) 88 (47–133) 0.0018
NT-proBNP, pg/mL; median (IQR) 4282 (2223–7397) 5490 (3604–14 575) 3581 (1568–6172)0.007
ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; AMI, acute myocardial infarction; ASA, acetylsalicylic
acid; CRP, C-reactive protein; cTn, cardiac troponin; ICD, implantable cardioverter defibrillator; IQR, interquartile range; LVEF, left ventric-
ular ejection fraction; NT-proBNP, N terminal pro brain natriuretic peptide; SD, standard deviation.
1Some data are missing; available number of patients (N) is indicated; for CRP, 142 samples were available at admission and eight (5.3%)
samples were obtained during hospitalization.
2Elevated cTn corresponds to cTnT ≥ 0.03 ng/mL or cTnI ≥ 0.035 ng/mL.
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identified a group with a particularly high risk of death
(with the group in which no biomarker or only one biomarker
was above the cut-off as a reference). After adjustment for
standard clinical variables, the combination of the biomarkers
remained independent predictors of mortality (HR 10.04 for
1 year mortality).
Based on the defined cut-off values, a Kaplan–Meier anal-
ysis of survival was performed. In the Kaplan–Meier analysis,
we compared the mortality in three or two patient groups di-
vided based on the CT-IGFBP-4, NT-proBNP, and CRP levels
(Figure 4).
The stratification of the patients into two groups according
to the NT-proBNP, CT-IGFBP-4, and CRP cut-off levels demon-
strated a significant improvement in the risk stratification
Figure 1 Correlation of N-terminal pro brain natriuretic peptide (NT-
proBNP), CT-IGFBP-4, and C-reactive protein (CRP) in a study cohort of
patients with acute heart failure.
Figure 2 N-terminal pro brain natriuretic peptide (NT-proBNP) (A), CT-
IGFBP-4 (B), and C-reactive protein (CRP) (C) concentrations at admission
in 1 year survivors and non-survivors with acute heart failure. The central
line represents median, box represents interquartile range, and whiskers
represent 5th and 95th percentiles.
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with the combined biomarkers. If the groups were divided
based on a single biomarker (NT-proBNP, CT-IGFBP-4, or
CRP) value, the subgroup of the patients who died in the
groups of elevated biomarkers ranged from 44.4% to 48.8%
compared with 14.0–20.0% in the groups of low biomarkers.
However, the stratification of the patients into two groups
according to the combination of NT-proBNP, CT-IGFBP-4,
and CRP indicated 51.0% mortality in the group in which
two or three biomarkers increased and only 5.0% in the
group in which one biomarker or no biomarkers increased
(Figure 4; Supporting Information, Table S1, Supplementary
materials).
The stratification of the patients into three groups was
more flat and informative as it enabled defining low, interme-
diate, and high risk groups of patients. While 54.8% died in
the ‘high risk’ group (high NT-proBNP and high CT-IGFBP-4),
no patient died in the ‘low risk’ group (low NT-proBNP and
low CT-IGFBP-4) during the 1 year follow-up period. The addi-
tion of CRP to NT-proBNP and CT-IGFBP-4 in the combined
analysis enabled defining a ‘very high risk’ group (all three
biomarkers increased) in which 76.9% of the patients died
during the 1 year follow-up period (Figure 4; Supporting In-
formation, Table S1).
Discussion
In the present study, we demonstrated that elevated
CT-IGFBP-4 was a strong predictor of all-cause mortality in
patients with AHF at both the 1 month and 1 year follow-
ups. CT-IGFBP-4 showed a weak or no correlation with
NT-proBNP and CRP, which likely reflected the different
molecular mechanisms involved in the elevation of these
biomarkers in AHF.
NT-proBNP is currently part of the recommended diagnos-
tic workup of suspected AHF. NT-proBNP is also widely inves-
tigated as the biomarker for the prognosis of mortality in
patients with AHF.9,18,20 Although NT-proBNP independently
predicted mortality in patients with AHF after adjustment
for standard clinical variables, such as age, gender, systolic
or diastolic blood pressure, heart rate, impaired renal func-
tion, glomerular filtration rate, sodium, and haemoglobin,12
NT-proBNP in its prognostic application is clearly far from
ideal. In most clinical studies, the ROC AUC values for short-
term mortality for NT-proBNP in patients with AHF are typi-
cally within 0.67–0.77.20,21 The use of additional biomarkers
in combination with NT-proBNP demonstrated a significant
increase in the prognostic value compared with NT-proBNP
alone.11–13 The search for novel biomarkers that maximally
contribute to the known prognostic biomarkers and clinical
variables is of substantial importance for early and effective
AHF management, which has progressed significantly in re-
cent years.22,23
IGFBP-4 fragments were initially established as prognostic
biomarkers of major adverse cardiac events (MACE) and
mortality in patients with cardiac ischaemia and type 1 diabe-
tes.19,24 Hjortebjerg et al.17 recently showed that NT-IGFBP-4
and CT-IGFBP-4 predict cardiac and all-cause mortality in a
group of 656 patients with ST-elevation myocardial infarction.
CT-IGFBP-4 demonstrates the best prognostic value in the
Figure 3 Receiver operator characteristic analysis of the clinical predic-
tion model, N-terminal pro brain natriuretic peptide (NT-proBNP), CT-
IGFBP-4, C-reactive protein (CRP), and their combinations. Prediction of
all-cause mortality at 1 month (A) and 1 year (B) by NT-proBNP, CT-
IGFBP-4, CRP, and their combinations. P < 0.001 for all ROC curves com-
pared with 0.5 curves.
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subgroup of these patients with left ventricular ejection frac-
tion (LVEF) 46 ± 9. García-Osuna et al. followed up 196 pa-
tients with ST-elevation myocardial infarction for 6 months.
The authors found that high CT-IGFBP-4 is associated with
an increased risk of future MACE.25
We hypothesized that CT-IGFBP-4 might be a prognostic
biomarker in patients with AHF. The most important finding
of the present study is that the combination of CT-IGFBP-4
and NT-proBNP provided a significant added value for the
prediction of mortality over NT-proBNP alone, even in the
limited number of patients (n = 156). CRP was also signifi-
cantly predictive for all-cause mortality in the ROC curve anal-
ysis; that is why CRP, along with CT-IGFBP-4 and NT-proBNP,
was included in the analysis of the prognostic value of combi-
nations of the analytes. We subsequently used a clinical
model that included standard variables predicting mortality
in patients with AHF as a comparator for additional bio-
markers. Other clinical variables such as New York Heart
Association (NYHA) class, LVEF value, or medical therapy did
not significantly add to the prognostic value of the model
and were not included into the model. It was found that
CT-IGFBP-4, in contrast to NT-proBNP and CRP, added signif-
icant prognostic value to the model. The inclusion of all three
biomarkers into the basic clinical model made the model even
stronger.
Kaplan–Meier and Cox proportional hazard regression
analyses supported the advantage of the combination of
CT-IGFBP-4, NT-proBNP, and CRP for all-cause mortality in pa-
tients with AHF. As mortality could be associated with many
factors such as age, heart rate, and others, multivariate HRs
models were adjusted for standard clinical variables. It was
previously speculated that some of the differences in IGFBP-
4 fragment concentrations in the circulation could be ex-
plained by distinct clearance rates.19 However, in patients
with AHF, CT-IGFBP-4 remained an independent predictor of
mortality after the inclusion of cystatin C into the multivariate
model (Table 2).
Notably, 52% of deaths occurred during the first month of
observation. Thus, it is important that the improvement was
demonstrated for the combination of NT-proBNP, CT-IGFBP-
4, and CRP in the 1 month follow-up period. The combination
of these three biomarkers enabled the selection of a group of
‘high risk’ patients, in which 50% patients died within
1 month, while no single patient died within 1 month in the
group of 60 (38.5%) patients who had one biomarker or no
biomarkers increased (Figure 4; Supporting Information,
Table S1). It has previously been shown that the admission
levels of NT-proBNP in patients with acute decompensated
HF are poorer predictors of adverse outcomes than levels of
this biomarker at 48 h or discharge (after a median 13 days
of hospitalization).21 Thus, the combination of the admission
levels of NT-proBNP, CT-IGFBP-4, and CRP can be a valuable
tool to guide immediate treatment decisions during the index
AHF hospitalization.
The lack of dependency of the biomarkers may explain the
significant added value of the combination of CT-IGFBP-4,
NT-proBNP, and CRP. The absence of a correlation or a very
weak correlation among all three biomarkers in the investi-
gated cohort (Figure 1) may indicate the different natures
and different pathophysiological functions of these proteins
in the development of HF.
Figure 4 Kaplan–Meier survival curve for patients according to N-termi-
nal pro brain natriuretic peptide (NT-proBNP), CT-IGFBP-4, and C-reactive
protein levels. The patients are divided into two groups (A) or three
groups (B) according to the NT-proBNP (‘Increased’: ≥3078 pg/mL) and
CT-IGFBP-4 (‘Increased’: ≥92.5 ng/mL) levels as indicated in the legends.
Log-rank P-values were <0.001 for all figures.
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The ability of CT-IGFBP-4 to predict mortality in patients
with AHF is rather surprising and currently does not fit well
into the accepted role and place of the PAPP-A/IGFBP-4/IGF
system in the pathogenesis of cardiovascular diseases. As
the products of IGFBP-4 cleavage under the action of metal-
loproteinase PAPP-A, IGFBP-4 fragments can reflect the clini-
cal value of PAPP-A. The majority of PAPP-A studies related to
cardiovascular diseases were performed in patients with
acute coronary syndrome or chest pain. The studies show
that measurements of blood PAPP-A could be of clinical value
for AMI diagnosis, as well as all-cause mortality, AMI, or
MACE prediction.26–28
Few studies have examined the prognostic significance of
PAPP-A in patients with established HF. In a recent study on
a group of 683 patients with NYHA HF Classes III–IV, the abil-
ity of PAPP-A to predict 7 year mortality was investigated.29
In a univariate Cox proportional hazard model, PAPP-
A > 10 mIU/L is a significant predictor of mortality. In a
2011 study, Funayama et al. examined mortality in 182 pa-
tients with HF with different NYHA classes during a mean
follow-up period of 796 days. The authors show that the
serum PAPP-A levels were related to the severity of HF and
associated with a higher risk for adverse cardiac events. In a
multivariate Cox proportional hazards regression model, both
BNP and PAPP-A are independent predictors of cardiac
events.30 On the basis of their data, Funayama et al. suggest
that PAPP-A might be involved in the pathogenesis of HF.
Thus, it can be assumed that the role of PAPP-A in the
pathogenesis of cardiovascular diseases is not limited to the
activation of proliferation of smooth muscle cells within ath-
erosclerotic plaques and destabilization of the plaques; it
may also be associated with myocardial remodelling that oc-
curs after AMI. Further research is clearly needed to clarify
the role of the PAPP-A/IGFBP-4/IGF regulatory system in
myocardial remodelling.
As a cardiovascular biomarker, IGFBP-4 fragments have
several advantages over PAPP-A, including several orders of
magnitude higher levels in circulation, a lack of interfering
complexes with other circulating proteins, and the indepen-
dence of the presence of heparin in the blood.31,32 The cur-
rent findings suggest that CT-IGFBP-4 could become an
important component of the prognostic assessment of pa-
tients with AHF, along with other biomarkers and clinical
variables.
At present, it seems that the best risk stratification of ad-
verse outcomes in patients with AHF can be obtained by a
combination of several circulating biomarkers and clinical var-
iables but not by any single biomarker. The advantage of the
multimarker approach in the prediction of AHF adverse out-
comes seems to be related to the variety of different pro-
cesses that occur during myocardial remodelling. The
mechanisms of pathological remodelling of the myocardium
of ischaemic and other origins have been actively studied in
recent years. Changes in the phenotypes of cardiomyocytes,
inflammation, cardiac fibrosis, and specific immune responses
related to HF may all provide a certain contribution to
the pathological changes of the heart. Each facet of the
process of myocardial remodelling can be reflected by
certain circulating biomarkers. Further studies on larger
samples of patients with HF at different stages will make it
possible to refine the prognostic ability of IGFBP-4 fragments
in this application and will also stimulate investigations of the
role of the PAPP-A/IGFBP-4/IGF axis in the pathophysiology
of HF.
Conclusions
CT-IGFBP-4 independently predicted all-cause mortality in pa-
tients with AHF. CT-IGFBP-4, together with NT-proBNP and
CRP, significantly improved the prognostic risk stratification
for all-cause mortality in patients with AHF.
Limitations
Additional clinical studies on larger cohorts of patients with a
larger number of different types of endpoints are needed to
confirm the value of IGFBP-4 fragments as a prognostic bio-
marker in HF. Unfortunately, we did not have enough data
to analyse cardiac mortality separately, as the reason for
death is only known for limited number of non-survivors.
We have data on eight patients having implantable
cardioverter defibrillator. However, this number is not
enough for reliable statistical analysis of the impact of im-
plantable cardioverter defibrillator on the management of
the patients within the investigated cohort. Some clinical
characteristics of patients were lacking (Table 1), which lim-
ited detailed analysis of the influence of these factors to
the prognostic value of CT-IGFBP-4. Management of patients
with HF enrolled in the study in 2004 might not necessarily
reflect modern clinical guidelines. Studies are needed to com-
pare IGFBP-4 fragments with other prospective biomarkers of
HF, such as galectin-3, growth differentiation factor-15, and
soluble suppression of tumorigenicity-2.
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